BioNTech

Develops personalized immunotherapies with a focus on cancer medicine.

Launch date

2008

Employees

1001-5000 people

Market cap

Net debt

-

Enterprise valuation

$3.7b (Public information from Jul 2024)

Company register number HRB 48720 (Mainz)

Mainz Rhineland-Palatinate (HQ)

https://www.biontech.com/

https://twitter.com/biontech_group https://www.linkedin.com/company/biontech-se/

Deals in current and previous year:

Revenues, earnings & profits over time

EUR	2020	2021	2022	2023	2024	2025	2026
Revenues	0000	0000	0000	0000	0000	0000	0000
% growth	344 %	3834 %	(9 %)	(78 %)	(27 %)	(2 %)	2 %
EBITDA	0000	0000	0000	0000	0000	0000	0000
% EBITDA margin	(9 %)	79 %	76 %	30 %	(23 %)	(28 %)	(32 %)
Profit	0000	0000	0000	0000	0000	0000	0000
% profit margin	3 %	54 %	55 %	24 %	(20 %)	(18 %)	(23 %)
EV / revenue	00.0x	00.0x	00.0x	00.0x	00.0x	00.0x	00.0x
EV / EBITDA	00.0x	00.0x	00.0x	00.0x	00.0x	00.0x	00.0x
R&D budget	0000	0000	0000	0000	0000	0000	0000
R&D % of revenue	134 %	-	-	47 %	-	-	-

Source: Dealroom estimates

Get premium to view all results

Date	Investors	Amount	Round
-	investor investor investor investor investor investor investor investor investor investor investor investor investor investor	$0.0	round
Dec 2019	investor	$0.0	round
Jun 2020	investor	$0.0	round
Jun 2020	investor	$0.0	round
Sep 2020	investor	$0.0	round
Apr 2022	N/A	$0.0	round
May 2024*	Coalition for Epidemic Preparedness	$145m	Grant
Total Funding		000k

Tech stackLearn more about the technologies and tools that this company uses.

Crescendo Biologics (Formerly Translocus)

Neon Therapeutics

ACQUISITION by BioNTech Jan 2020

exited

ACQUISITION by BioNTech Jan 2023

PhagoMed Biopharma

ACQUISITION by BioNTech Nov 2021

AexeRNA Therapeutics

ACQUISITION by BioNTech Nov 2023